{"entity":{"id":"nct01956734","kind":"trial","name":"Virus DNX2401 and Temozolomide in Recurrent Glioblastoma","aka":[],"tldr":"A phase 1 trial of DNX-2401 run by Clinica Universidad de Navarra, Universidad de Navarra, completed.","summary":"Virus DNX2401 and Temozolomide in Recurrent Glioblastoma is a phase 1 interventional study registered as NCT01956734 by Clinica Universidad de Navarra, Universidad de Navarra, with 31 participants enrolled, started 2013-09. Conditions recorded: Glioblastoma Multiforme and Recurrent Tumor. Interventions recorded: DNX2401 and Temozolomide.","status":"completed","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT01956734","url":"https://clinicaltrials.gov/study/NCT01956734"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["glioblastoma","metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["dnx-2401"],"companies":["dnatrix"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT01956734","phase":"1","setting":"Phase I Trial of Combination of DNX-2401 (Formerly Named Delta-24-RGD) Oncolytic Adenovirus With a Short Course of Temozolomide for Treatment of Glioblastoma at First Recurrent","sponsor":"Clinica Universidad de Navarra, Universidad de Navarra","enrolled":31,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct01956734/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"},{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"dnx-2401","kind":"drug","name":"DNX-2401","route":"/drugs/dnx-2401/"}],"company":[{"id":"dnatrix","kind":"company","name":"DNAtrix","route":"/companies/dnatrix/"}]}}